• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMJ Open . Defining the preadmission factors that modify risk of acute complications, survival and long-term recovery from COVID-19: prospective, long

tetano

Editor, Senior Moderator
BMJ Open

. 2026 Sep 21;16(9):e109653.
doi: 10.1136/bmjopen-2025-109653.

Defining the preadmission factors that modify risk of acute complications, survival and long-term recovery from COVID-19: prospective, longitudinal, multisite, cohort study based in England​


H E Baxendale 1 2 , Martin Law 3 4 , Claire Matthews 3 , Janet Piggott 5 , Rama Vancheeswaran 6 , Alain Vuylsteke 7 , Catherine Wilson 7 , Erin Hopley 7 , Mark Toshner 7 8 , Iryna Boubriak 7 , Joseph Newman 7 8 , Nasir Hannan 9 , Alexander Jk Wilkinson 9 10 , Andrew Barlow 6 , Nicole Harriott 9 , Nicola Jones 7 2 , Stephen Webb 7 , William Schwaeble 11 , Jonathan Heeney 11 , Dominique Couturier 3 4

Affiliations Expand


Abstract​


Objectives: To understand the pre-admission factors associated with COVID-19 clinical outcome with and without controlling for acute COVID-19 severity score.


Design: We ran a prospective, longitudinal, multicentre cohort study.


Setting: Patients were recruited from four hospitals and one community General Practice in England PARTICIPANTS: 425 patients with COVID-19 from the start of the UK pandemic in April 2020 through the first three waves with study completing in 2022.


Primary and secondary outcome measures: Data were collected and analysed to identify demographic factors and preadmission symptoms for hospitalised patients that were associated with COVID-19 disease severity at recruitment, acute clinical course and long-term recovery. Analysis methods included logistic regression, time-to-event analysis, mixed-effect models and K-medoids clustering.


Results: The cohort was skewed to patients with severe COVID (60%). Preadmission symptom cluster was associated with risk of thrombosis (OR 2.7 (95% CI 1.6 to 6.1), p=0.021) and renal disease (OR 3.3 (95% CI 1.4 to 8.0), p=0.008). Duration of symptoms less than 1 week was associated with pneumothorax (OR 3.1 (95% CI 1.2 to 8.3), p=0.025). Renal complications were more likely to be seen in the first wave compared with the second wave of the pandemic (OR 3.4 (95% CI 1.5 to 7.5), p=0.003). Using a logistic regression model, survival to discharge was associated with white (vs unknown) ethnicity (OR 6.6 (95% CI 2.8 to 15.2), p<0.0001), lower age (<40 years vs >60 years, OR 4.9 (95% CI 1.2 to 20.0), p=0.027) and absence of comorbidities (OR 2.7 (95% CI 1.2 to 5.9), p=0.016). However, using a survival model, hazard of death was increased for all hospitalised who had duration of symptoms less than 1 week (HR 5.6 (95% CI 1.3 to 24.4), p=0.023) or had comorbidities (HR 33.3 (95% CI 3.1 to 333.3), p=0.0035). Over 80% of patients reported long-term sequelae with neuromuscular and cognitive effects dominating early on and mood disturbance and breathlessness persisting to 12 months. Gender had the strongest association with dyspnoea (OR 99.8 (95% CI 2.4 to 4123.1, p=0.02) and persistent mood disorder (OR 8.3 (95% CI 1.7 to 39.9), p=0.008) and associated with persistent gastrointestinal problems (loose bowels (OR 3.3 (95% CI 1.1 to 10.8), p=0.045), abdominal pain (OR 5.0 (95% CI 1.4 to 18.1), p=0.014), constipation (OR 3.8 (95% CI 1.6 to 9.2), p=0.003)) and cognitive problems (OR 2.3 (95% CI 1.1 to -4.8), p=0.024).


Conclusions: These results support an association between specific demographic factors and early infection symptoms that impact on acute and long-term outcomes of COVID-19 in this cohort after accounting for COVID-19 disease severity at enrolment. Understanding the disease mechanisms that explain these relationships is needed to inform targeted therapeutics to prevent and/or manage these complications.

Keywords: Adult intensive & critical care; COVID-19; EPIDEMIOLOGY; Post-Acute COVID-19 Syndrome.
 
Back
Top Bottom